Citations

Clear

1526 citation(s) found for "Sun, Yu".

Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor
Zhang, Beilu, Tan, Ming , Wang, Jinping , Feinman, Rena , Liou, Hsiou‐Chi , Ouk, Samedy , Bariana, Manpreet , Sun, Jingyu , Cassella, Elena , Rateshwar, Janice , Wang, Weiwei , Siegel, David S. , Mondello, Patrizia , Wang, Hongjun , Zakrzewski, Johannes L.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6018-6019

10.1182/blood-2022-160324 Get It

FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort
St‐Pierre, Frédérique , Kocherginsky, Masha , Quon, Andrew , Baratto, Lucia , Kostakoğlu, Lale , Evens, Andrew M. , Evens, Andrew M , Broski, Stephen M. , Sun, Zequn , Savas, Hatice , Winter, Jane N. , Witzig, Thomas E. , Kahl, Brad S. , Gordon, Leo I.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6480-6481

10.1182/blood-2022-162114 Get It

Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses
Flietner, Evan, Yu, Mei , Zhou, Yun , Feng, Yubin, Wen, Zhi , Sun, Yuqian, Burns, Robert, Patnaik, Mrinal M. , Asimakopoulos, Fotis , Zhang, Jing , Rajagopalan, Adhithi , Veltri, Anthony J. , Lasho, Terra L. , Callander, Natalie S. , Wang, Demin

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9935-9936

10.1182/blood-2022-162827 Get It

Body mass index and molecular subtypes of colorectal cancer
Murphy, Neil , Newton, Christina C. , Papadimitriou, Nikos , Hoffmeister, Michael , Phipps, Amanda I. , Harrison, Tabitha A. , Aglago, Elom K. , Berndt, Sonja I. , Brenner, Hermann , Cao, Yin , Chang‐Claude, Jenny , French, Amy J. , Gallinger, Steven , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harlid, Sophia , Huang, Wen‐Yi , Laskar, Ruhina Shirin , Mandic, Marko , Nowak, Johnathan A., Obón‐Santacana, Mireia , Steinfelder, Robert S. , Thibodeau, Stephen N. , Trinh, Quang M. , Tsilidis, Kostas K, Guelpen, Bethany Van , Wang, Xiaoliang , Woods, Michael O. , Zaidi, Syed Hassan Ejaz , Gunter, Marc J. , Peters, Ulrike , Song, Mingyang , Song, Mingyang , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann , Cao, Yin , Chen, Xuechen , Drew, David A , Harlid, Sophia , Huang, Wen-Yi , Marchand, Loïc Le , Limburg, Paul, Sun, Wei , Ugai, Tomotaka , Van Guelpen, Bethany , Wang, Xiaoliang , Woods, Michael O , Gunter, Marc J , Murphy, Neil , Song, Mingyang , Aglago, Elom K , Obón-Santacana, Mireia , Papadimitriou, Nikos , Mandic, Marko , Trinh, Quang M , Georgeson, Peter , Newcomb, Polly A. , Buchanan, Daniel D. , Chan, Andrew T. , Cheng, Iona C. , Dimou, Niki , Drew, David A. , Farris, Alton B. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Marchand, Loı̈c Le , Limburg, Paul J. , Lin, Yi , Ogino, Shuji , Qu, Conghui , Sakoda, Lori C. , Schoen, Robert E. , Southey, Melissa C. , Stadler, Zsofia , Sun, Wei , Toland, Amanda Ewart , Tsilidis, Kostas K, Campbell, Peter T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 26, 2022 | Volume: 115 | Issue: 2 | Pages: 165-173

10.1093/jnci/djac215 | PMID 36445035 Get It

Abstract Background Obesity is an established risk factor for colorectal cancer (CRC), but the evidence for the association is inconsistent across molecular subtypes of the disease. Methods We pooled data on body mass index (BMI), tumor microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, and Jass classification types for 11 872 CRC cases and 11 013 controls from 11 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for covariables. Results Higher BMI was associated with increased CRC risk (OR per 5 kg/m2 = 1.18, 95% CI = 1.15 to 1.22). The positive association was stronger for men than women but similar across tumor subtypes defined by individual molecular markers. In analyses by Jass type, higher BMI was associated with elevated CRC risk for types 1-4 cases but not for type 5 CRC cases (considered familial-like/Lynch syndrome microsatellite instability-H, CpG island methylator phenotype-low or negative, BRAF-wild type, KRAS-wild type, OR = 1.04, 95% CI = 0.90 to 1.20). This pattern of associations for BMI and Jass types was consistent by sex and design of contributing studies (cohort or case-control). Conclusions In contrast to previous reports with fewer study participants, we found limited evidence of heterogeneity for the association between BMI and CRC risk according to molecular subtype, suggesting that obesity influences nearly all major pathways involved in colorectal carcinogenesis. The null association observed for the Jass type 5 suggests that BMI is not a risk factor for the development of CRC for individuals with Lynch syndrome.
Ultrasensitive US Microvessel Imaging of Hepatic Microcirculation in the Cirrhotic Rat Liver
Zhang, Wei , Huang, Chengwu , Yin, Tinghui , Miao, Xiaoyan , Deng, Huan , Zheng, Rongqin , Ren, Jie , Chen, Shigao , Huang, Chengwu

Mayo Clinic

Radiology | November 22, 2022 | Volume: 307 | Issue: 1 | Pages: No page available

10.1148/radiol.220739 | PMID 36413130 Get It

Automated Detection of Surgical Implants on Plain Knee Radiographs Using a Deep Learning Algorithm
Kim, Back , Lee, Do Weon , Lee, Sanggyu , Ko, Sunho , Jo, Changwung , Park, Jaeseok , Choi, Byung Sun , Krych, Aaron J. , Pareek, Ayoosh , Han, Hyuk‐Soo , Ro, Du Hyun , Krych, Aaron J

Mayo Clinic

Medicina | November 21, 2022 | Volume: 58 | Issue: 11 | Pages: 1677

10.3390/medicina58111677 | PMID 36422216 Get It

Background and Objectives: The number of patients who undergo multiple operations on a knee is increasing. The objective of this study was to develop a deep learning algorithm that could detect 17 different surgical implants on plain knee radiographs. Materials and Methods: An internal dataset consisted of 5206 plain knee antero-posterior X-rays from a single, tertiary institute for model development. An external set contained 238 X-rays from another tertiary institute. A total of 17 different types of implants including total knee arthroplasty, unicompartmental knee arthroplasty, plate, and screw were labeled. The internal dataset was approximately split into a train set, a validation set, and an internal test set at a ratio of 7:1:2. You Only look Once (YOLO) was selected as the detection network. Model performances with the validation set, internal test set, and external test set were compared. Results: Total accuracy, total sensitivity, total specificity value of the validation set, internal test set, and external test set were (0.978, 0.768, 0.999), (0.953, 0.810, 0.990), and (0.956, 0.493, 0.975), respectively. Means ± standard deviations (SDs) of diagonal components of confusion matrix for these three subsets were 0.858 ± 0.242, 0.852 ± 0.182, and 0.576 ± 0.312, respectively. True positive rate of total knee arthroplasty, the most dominant class of the dataset, was higher than 0.99 with internal subsets and 0.96 with an external test set. Conclusion: Implant identification on plain knee radiographs could be automated using a deep learning technique. The detection algorithm dealt with overlapping cases while maintaining high accuracy on total knee arthroplasty. This could be applied in future research that analyzes X-ray images with deep learning, which would help prompt decision-making in clinics.
Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH
Zhao, Xue-Qiao , Hippe, Daniel S. , Isquith, Daniel , Cantón, Gádor , Yamada, Kiyofumi , Balu, Niranjan , Crouse, John R., Anderson, Todd J. , Huston, John , O’Brien, Kevin D. , Yuan, Chun , Investigators, for the AIM-HIGH Carotid MRI Substudy, Huston, John , Hippe, Daniel S , Yamada, Kiyofumi , O'Brien, Kevin D , Hatsukami, Thomas S , Yuan, Chun , Sun, Jie , Investigators, for the AIM-HIGH Carotid MRI Substudy

Mayo Clinic

Circulation: Cardiovascular Imaging | November 15, 2022 | Volume: 15 | Issue: 11 | Pages: No page available

10.1161/circimaging.122.014229 | PMID 36378778 Get It

Background: Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy. Methods: In total, 214 AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein/High Triglycerides: Impact on Global Health Outcomes) participants with clinically established ASCVD and low high-density lipoprotein cholesterol received cartoid MRI at baseline and 2 years to assess changes in carotid morphology and composition. Patients were randomized to extended-release niacin or placebo, and all received simvastatin with optional ezetimibe as necessary to lower low-density lipoprotein cholesterol to 40 to 80 mg/dL. Changes in lipid content and carotid morphology were tested using the Wilcoxon signed-rank test. Differences between subjects with and without IPH and between subjects assigned extended-release niacin or placebo were tested using the Wilcoxon rank-sum test. Linear regression was used to test the association of IPH and lipid content changes after adjusting for clinical risk factors. Results: Among 156 patients (61±9 years; 81% men) with complete MRI, prior statin use: <1 year, 26%; 1 to 5 years, 37%; >5 years, 37%. Triglycerides and ApoB decreased significantly, whereas high-density lipoprotein cholesterol and ApoA1 increased significantly over time. Plaque lipid content was significantly reduced (−0.5±2.4 %/year, P = 0.017) without a significant difference between the 2 treatment groups. However, the lipid content increased in plaques with IPH but regressed in plaques without IPH (1.2±2.5 %/year versus −1.0±2.2, P = 0.006). Additionally, IPH was associated with a decrease in lumen area (−0.4±0.9 mm2/year versus 0.3±1.4, P = 0.033). IPH remained significantly associated with increase in lipid content in multivariable analysis (54.4%, 95% CI: 26.8, 88.0, P < 0.001). Conclusions: Carotid plaques under continued intensive lipid-lowering therapy moved toward stabilization. However, plaques with IPH showed greater increases in lipid content and greater decreases in lumen area than plaques without IPH. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01178320.
In Situ Metabolomics of Cortisol-Producing Adenomas
Murakami, Masanori , Sun, Na , Li, Fengxia , Feuchtinger, Annette , Gómez-Sánchez, Celso E. , Faßnacht, Martin , Reincke, Martín , Walch, Axel , Kroiß, Matthias , Beuschlein, Felix , Bancos, Irina , Beuschlein, Felix , Kroiss, Matthias , Fassnacht, Martin , Murakami, Masanori , Bancos, Irina

Mayo Clinic

Clinical Chemistry | November 14, 2022 | Volume: 69 | Issue: 2 | Pages: 149-159

10.1093/clinchem/hvac191 | PMID 36544353 Get It

Received June 8, 2022; accepted October 11, 2022 Background Recent advances in omics techniques have allowed detailed genetic characterization of cortisol-producing adrenal adenoma (CPA). In contrast, the pathophysiology of CPAs has not been elucidated in detail on the level of tumor metabolic alterations. Methods The current study conducted a comprehensive mass spectrometry imaging (MSI) map of CPAs in relation to clinical phenotypes and immunohistochemical profiles of steroidogenic enzymes. The study cohort comprised 46 patients with adrenal tumors including CPAs (n 35) and nonfunctional adenomas (n 11). Results Severity of cortisol hypersecretion was significantly correlated with 29 metabolites (adjusted P 0.05). Adrenal androgens derived from the classic androgen pathway were inversely correlated with both cortisol secretion (rs 0.41, adjusted P 0.035) and CYP11B1 expression (rs 0.77, adjusted P 2.00E-08). The extent of cortisol excess and tumor CYP11B1 expression further correlated with serotonin (rs 0.48 and 0.62, adjusted P 0.008 and 2.41E-05). Tumor size was found to be correlated with abundance of 13 fatty acids (adjusted P 0.05) and negatively associated with 9 polyunsaturated fatty acids including phosphatidic acid 38:8 (rs 0.56, adjusted P 0.009). Conclusions MSI reveals novel metabolic links between endocrine function and tumorigenesis, which will further support the understanding of CPA pathophysiology.
SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , O’Brien, Barbara , Sloan, Andrew, Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Groot, John de , Kim, Albert Sungsoo , Fecci, Peter E. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii256-vii257

10.1093/neuonc/noac209.989 Get It

Abstract Treatment options for glioblastoma remain limited, particularly for those who are not eligible for traditional resection, whether due to lesion location or inability to tolerate open craniotomy. Maximal-safe resection followed by radiation with concurrent and adjuvant temozolomide offers the best outcomes for patients. Unfortunately, not all tumors are amenable to conventional surgical resection at the time of diagnosis with only about 1/3 of patients able to receive a gross-total resection and 15-25% of patients receiving biopsy only, thus reducing their projected overall survival to 9 months. Laser interstitial thermal therapy (LITT) is a minimally invasive, cytoreductive tool, that has demonstrated safety as a surgical approach to treat primary brain tumors. METHODS Data from LAANTERN prospective multicenter registry (NCT02392078) was analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma (N=89). Demographics, intraprocedural data, adverse events, KPS, health-economics, and survival data were prospectively collected then analyzed separately for newly diagnosed GBM (N=29) and recurrent GBM (N=60). RESULTS Median overall-survival was 9.73 months (95% CI: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 (6.94, 12.36) months for recurrent patients. Median overall-survival for newly diagnosed patients receiving post-LITT chemoradiotherapy was 16.14 months (6.11, not reached). The median length of hospital stay was 50 hours and 80% of patients were discharged to home. CONCLUSIONS LITT offers an effective cytoreductive approach for patients with newly diagnosed and recurrent IDH wild-type glioblastoma. Importantly, its use in newly diagnosed patients who receive post-LITT chemoradiotherapy leads to a median OS similar to that of patients treated with conventional surgical resection. LITT remains an important alternative for patients with inoperable tumors or those not amenable to resection. Enrollment in LAANTERN is ongoing and these cohorts will be revisited as data continues to mature. Benefits beyond cytoreduction are also being actively explored.